ライフサイエンスコーパス: pregabalin

1 r day for duloxetine, and 600 mg per day for pregabalin).

2 norphine) and gabapentinoids (gabapentin and pregabalin).

3 ne, topiramate, brivaracetam, zonisamide, or pregabalin.

4 etic-neuralgia patient abruptly discontinued pregabalin.

5 balin-placebo while group 2 received placebo-pregabalin.

6 inephrine reuptake inhibitor, gabapentin, or pregabalin.

7 g Administration-approved drugs baclofen and pregabalin.

8 randomly assigned: 117 to placebo and 116 to pregabalin.

9 ain processing may respond to agents such as pregabalin.

10 te to precursors for GABA analogues, such as pregabalin.

11 cium-independent) dye release are reduced by pregabalin.

12 However, pregabalin 1 was active in the DBA/2 model after oral (a

13 0 mg/day of pregabalin (-9.2), 600 mg/day of pregabalin (-10.3), and lorazepam (-12.0) were significa

14 loxetine; 150-mg, 300-mg, 450-mg, and 600-mg pregabalin; 100-mg and 200-mg milnacipran; and amitripty

15 n 300 mg per day, pregabalin 300 mg per day, pregabalin 150 mg per day, and pregabalin 75 mg per day.

16 y disorder were randomly assigned to receive pregabalin (150 mg/day or 600 mg/day), lorazepam (6 mg/d

17 received daily treatment, 182 with 300 mg of pregabalin, 178 with 0.25 mg of pramipexole, 180 with 0.

18 ac plus tizanidine (-26.1 (-38.5 to -13.6)), pregabalin (-24.7 (-34.6 to -14.7)), and 14 other medici

19 Different doses of pregabalin (30, 60, 90, and 120 mg/kg) were used to asse

20 n 600 mg per day, gabapentin 300 mg per day, pregabalin 300 mg per day, pregabalin 150 mg per day, an

21 point compared with placebo (-8.4 +/- 0.8): pregabalin, 300 mg (-12.2 +/- 0.8, P<.001), 450 mg (-11.

22 were randomized to 4 weeks of treatment with pregabalin, 300 mg/d (n = 91), 450 mg/d (n = 90), or 600

23 zed, double-blinded, crossover trial of oral pregabalin (50-300 mg/d) vs placebo was conducted at 2 s

24 Mice treated with pregabalin 60 and 90 mg/kg doses demonstrated drug seeki

25 r 30 min, the mice received either saline or pregabalin (60 mg/kg) during the conditioning phase.

26 tine (nine of 14 studies); 7.7 (6.5-9.4) for pregabalin; 7.2 (5.9-9.21) for gabapentin, including gab

27 ven placebo (73%, N=50 of 69), 600 mg/day of pregabalin (71%, N=50 of 70), or 150 mg/day or pregabali

28 0 mg per day, pregabalin 150 mg per day, and pregabalin 75 mg per day.

29 le score in the patients given 150 mg/day of pregabalin (-9.2), 600 mg/day of pregabalin (-10.3), and

30 egabalin (71%, N=50 of 70), or 150 mg/day or pregabalin (90%, N=62 of 69).

31 nt pathways: amitriptyline supplemented with pregabalin (A-P), pregabalin supplemented with amitripty

32 In these mice, local infusion of pregabalin, a clinically approved drug for fibromyalgia

33 y adds to our understanding of the action of pregabalin, a drug used for treatment of partial seizure

34 Previously, we demonstrated that pregabalin, a drug with high affinity and selectivity fo

35 igned to evaluate the efficacy and safety of pregabalin, a novel alpha(2)-delta ligand, for treatment

36 but not GluK2, currents in HEK293 cells, and pregabalin abolished this augmentation.

37 Recently, pregabalin abuse has been a focus for many healthcare ag

38 We previously evaluated the possibility of pregabalin abuse using the conditioned place preference

39 a lead compound for developing treatment for pregabalin abuse.

40 -5-phosphonopentanoic acid], suggesting that pregabalin action depends on NMDA receptor activation.

41 ng surgery, operative time, and preoperative pregabalin administration.

42 The central acting gabapentoid pregabalin affords a modest 12% pain reduction in patien

43 Molecular docking studies of pregabalin against CACNA2D1 of mouse, rabbit, and human

44 reating fibromyalgia, compared with placebo, pregabalin alone is associated with a small increase in

45 potent neuropathic analgesics gabapentin and pregabalin (alpha2delta-1 and alpha2delta-2), were also

46 d by co-treatment with the NMDAR antagonist, pregabalin (an alpha2delta-1 inhibitory ligand), or alph

47 Pregabalin, an alpha(2)delta-1/-2 ligand, and an alpha(2

48 led crossover design, we also tested whether pregabalin, an analgesic drug with proven efficacy on th

49 A series of pregabalin analogues were prepared and evaluated for the

50 nderwent randomization, of whom 108 received pregabalin and 101 received placebo; after randomization

51 95% CI, 15.3-21.6) per 1000 person-years for pregabalin and 12.5 (95% CI, 11.9-13.2) per 1000 person-

52 ies, of whom 18 622 (7.6%) were new users of pregabalin and 227 615 (92.4%) were new users of gabapen

53 ted by syntheses of the anticonvulsant agent pregabalin and a brivaracetam precursor.

54 Pregabalin and alprazolam produced a significantly great

55 peripheral edema and burning sensation with pregabalin and capsaicin.

56 cing pain, and newly developed ones, such as pregabalin and duloxetine, while specifically marketed f

57 30%), carbamazepine (26%), topiramate (25%), pregabalin and gabapentin (10%).

58 Both pregabalin and gabapentin are common nonopioid medicatio

59 The optimal dosage of pregabalin and gabapentin for pain control and safety in

60 f neuropathic pain are gabapentinoids (e.g., pregabalin and gabapentin).

61 he most frequent adverse events reported for pregabalin and lorazepam were somnolence and dizziness.

62 Participants received both pregabalin and matched placebo (titrated to a maximum-to

63 n, nortriptyline and duloxetine outperformed pregabalin and mexiletine when pain reduction and undesi

64 he primary analyses involved a comparison of pregabalin and placebo over a period of 12 weeks with us

65 nce in the mean pain and itch scores between pregabalin and placebo treatment (measured using VAS) be

66 Doses of pregabalin and placebo were increased over 4 weeks.

67 d a comparison of rates of augmentation with pregabalin and pramipexole over a period of 40 or 52 wee

68 of the alpha-2-delta ligands (gabapentin and pregabalin) and the norepinephrine/serotonin reuptake in

69 nortriptyline, 0.43 for duloxetine, 0.05 for pregabalin, and 0.00 for mexiletine.

70 serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin; a weak recommendation for us

71 us adverse events reported by patients given pregabalin, and no withdrawal syndrome was associated wi

72 vior, and could be rescued by the analgesic, pregabalin, and the libido-enhancing drugs, apomorphine

73 Acute pregabalin application reversibly dilated pressurized ar

74 ralgia compared with placebo, gabapentin and pregabalin are associated with a modest increase in the

75 tine and milnacipran--and the anticonvulsant pregabalin are encouraging.

76 Gabapentin and pregabalin are inhibitory ligands of both alpha2delta-1

77 in that all four manufacturing steps to make pregabalin are performed in water.

78 Gabapentin and pregabalin are structurally related compounds with recog

79 Gabapentinoids, gabapentin and pregabalin, are recommended in multimodal analgesia prot

80 In the pregabalin arm, 45 patients (38.8%) achieved the primary

81 (P = .009 and P = .007, comparing respective pregabalin arms to the placebo arm).

82 cities were significantly more common in the pregabalin arms, being more evident with the higher dose

83 get 75 mg twice daily and 150 mg twice daily pregabalin arms, respectively (P = .009 and P = .007, co

84 ovides support and a mechanism of action for pregabalin as a possible effective therapy in the treatm

85 n in patients with RLS who were treated with pregabalin as compared with placebo and pramipexole.

86 Pregabalin at 300 and 450 mg/day was associated with sig

87 Pregabalin at 450 mg/day improved several domains of hea

88 Pregabalin at 450 mg/day significantly reduced the avera

89 Pregabalin at 450 mg/day was efficacious for the treatme

90 nts were randomly assigned to receive either pregabalin at a dose of 150 mg per day that was adjusted

91 signed to receive 52 weeks of treatment with pregabalin at a dose of 300 mg per day or pramipexole at

92 -cancer pain, gabapentinoids (gabapentin and pregabalin), benzodiazepines, and Z-drugs (zopiclone, za

93 -delta Type 1 substantially reduces specific pregabalin binding in CNS regions that are known to pref

94 In mutant mice, pregabalin binding was robust throughout regions where t

95 In vitro studies have shown that pregabalin binds with high affinity to the alpha(2)-delt

96 rrespondingly, inhibiting alpha2delta-1 with pregabalin, Cacna2d1 genetic knock-out, or disrupting al

97 am, carbamazepin, oxcarbazepine, gapapentin, pregabalin, clonazepam, or phenobarbital.

98 three-step synthesis of the medicinal agent pregabalin (commercialized by Pfizer under the trade nam

99 n, incident HF was increased in new users of pregabalin compared with new users of gabapentin.

100 ence was also noted among patients receiving pregabalin compared with those receiving gabapentin (AHR

101 Molecular docking analyses and QSPR of pregabalin confirmed its suitability as a new IOP-loweri

102 Gabapentinoids (gabapentin and pregabalin) could be repurposed for treating calcineurin

103 line (P-A), and duloxetine supplemented with pregabalin (D-P), each pathway lasting 16 weeks.

104 the basis of preliminary promising data that pregabalin decreased hot flashes.

105 Pregabalin decreases hot flashes and is reasonably well

106 taNIH-CPSI score difference = -2.5 to -1.7), pregabalin (DeltaNIH-CPSI score difference = -2.4), and

107 Treatment with pregabalin did not significantly reduce the intensity of

108 In short-term treatment, pregabalin does not appear to have the withdrawal sympto

109 The mean pregabalin dose was generally well tolerated.

110 ) associated with amitriptyline (off-label), pregabalin, duloxetine, and milnacipran (on-label) in re

111 label for the treatment of fibromyalgia, but pregabalin, duloxetine, and milnacipran are the only pha

112 However, the mechanisms by which pregabalin exerts its therapeutic effects are not yet co

113 Pregabalin exhibits robust activity in preclinical assay

114 Prolonged (24-hour) pregabalin exposure did not alter total alpha(2)delta-1

115 y, these outcomes greatly support the use of pregabalin eye drops as once daily IOP-lowering therapy

116 triptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neur

117 rget of gabapentinoids (e.g., gabapentin and pregabalin) frequently used for treating patients with n

118 l of 227 adverse events were reported in the pregabalin group and 124 in the placebo group.

119 sted leg-pain intensity score was 3.4 in the pregabalin group and 3.0 in the placebo group (adjusted

120 sted leg-pain intensity score was 3.7 in the pregabalin group and 3.1 in the placebo group (adjusted

121 Dizziness was more common in the pregabalin group than in the placebo group.

122 verse events was significantly higher in the pregabalin group than in the placebo group.

123 Of the 5 treatment groups, the 300-mg pregabalin group was the only medication group that diff

124 cebo; after randomization, 2 patients in the pregabalin group were determined to be ineligible and we

125 observation-carried-forward end point, the 3 pregabalin groups and the alprazolam group had significa

126 ntly (P<.02) improved by the 300- and 600-mg pregabalin groups, but not by the 450-mg pregabalin (wee

127 ns with IRSAD, while tramadol, atenolol, and pregabalin had strong negative correlation with IRSAD.

128 Because pregabalin has greater potency than gabapentin in bindin

129 ng youth, however the addictive potential of pregabalin has not been well established.

130 Zonisamide and pregabalin have recently obtained licences as adjuvant t

131 Gabapentin and pregabalin in bipolar disorder, anxiety states, and inso

132 The role of pregabalin in CIBP with a clinical neuropathic pain comp

133 um channels is the major binding protein for pregabalin in CNS.

134 provided preliminary data on the efficacy of pregabalin in managing pain and itch in RDEB and gathere

135 Our findings do not support the role of pregabalin in patients with CIBP receiving radiotherapy.

136 The aim of this study was to examine pregabalin in patients with CIBP receiving radiotherapy.

137 d, double-blind, placebo-controlled trial of pregabalin in patients with sciatica.

138 atically reduces alpha(2)-delta 1 binding to pregabalin in vitro.

139 Acute systemic administration of pregabalin in vivo also selectively prevented the migrat

140 ral nervous system (CNS) binding protein for pregabalin in vivo, a mutant mouse with an arginine-to-a

141 ) mice, the acute systemic administration of pregabalin increased the threshold for SD initiation in

142 These results suggest that pregabalin-induced CPP was successfully modulated by CEF

143 le involvement of dopaminergic receptor-1 in pregabalin-induced CPP.

144 eceptors with SKF-83566 completely prevented pregabalin-induced place preference, thus demonstrating

145 the engagement of the dopaminergic system in pregabalin-induced reward-related behavior.

146 nstriction ("myogenic tone"), and attenuated pregabalin-induced vasodilation.

147 At the cellular level, pregabalin inhibited glutamatergic synaptic transmission

148 Pregabalin inhibits release of excess excitatory neurotr

149 ntrolled medical or psychiatric condition or pregabalin intolerance or allergy were excluded.

150 Pregabalin is a synthetic amino acid compound effective

151 These results indicate that pregabalin is an effective, rapidly acting, and safe tre

152 the intraocular pressure-lowering effect of pregabalin is dependent on the Cacna2d1 haplotype.

153 Pregabalin is effective in the treatment of some types o

154 The effect of pregabalin is not apparent in the presence of an N-methy

155 antiepileptic drugs (topiramate, lacosamide, pregabalin, levetiracetam), hypothermia, magnesium, pyri

156 Pregabalin lost its inhibitory effect on GluK1 currents

157 Pregabalin (Lyrica(R)) is produced using a lipase based

158 The antiepileptic pregabalin (Lyrica) shows clinical promise for migraine

159 Recent reports suggest illicit pregabalin (Lyrica) use may be increasing among youth, h

160 Morphine and pregabalin markedly alleviated pressure hyperalgesia, wh

161 Also, pregabalin markedly attenuated the amplitude of excitato

162 Pregabalin may be an effective alternative.

163 delta subunit of the L-type calcium channel, pregabalin may be associated with an increased risk for

164 r, laboratory and clinical work suggest that pregabalin may be useful in treating CIBP.

165 This study examined whether pregabalin may reduce the intensity of sciatica.

166 95% credible interval [CrI] -4.13 to -2.13), pregabalin (MD -2.79, 95% CrI -3.69 to -1.91), venlafaxi

167 enhancement, a single topical application of pregabalin ME can provide an extended IOP reduction of m

168 ted calcium channels binds to gabapentin and pregabalin, mediating the analgesic action of these drug

169 lds up to 74%, including the important drugs pregabalin, memantine, and the antimalarial artemisinin.

170 In addition, pregabalin microemulsion demonstrated good physical stab

171 The current study was designed to evaluate pregabalin microemulsion eye drops and to estimate its e

172 Pregabalin microemulsion eye drops were characterized us

173 rtriptyline (n = 134), duloxetine (n = 126), pregabalin (n = 73), or mexiletine (n = 69).

174 However, neither pregabalin nor alpha2delta-2 C-terminus peptide had sign

175 The effects of pregabalin on dye release are masked in the presence of

176 Finally, the action of pregabalin on dye release is most apparent before and ea

177 acebo with those of 150, 300, and 450 mg/day pregabalin on pain, sleep, fatigue, and health-related q

178 The authors examine the effects of pregabalin on presynaptic function of cultured hippocamp

179 Furthermore, inhibiting a2d-1 with pregabalin or disrupting the a2d-1-NMDAR interaction wit

180 trials conducted among patients who received pregabalin or gabapentin while undergoing spine surgery

181 Gabapentinoids (pregabalin or gabapentin).

182 delines recommend amitriptyline, duloxetine, pregabalin, or gabapentin as initial analgesic treatment

183 [1-(aminomethyl)cyclohexaneacetic acid] and pregabalin (PGB) [(S)-(+)-3-isobutyl-GABA or (S)-3-(amin

184 The therapeutic drugs gabapentin and pregabalin (PGB), which are both alpha(2)delta ligands,

185 Group 1 received a sequence of pregabalin-placebo while group 2 received placebo-pregab

186 Asymmetric hydrogenation of CI-1008 (pregabalin) precursors, 39 and 40, provided good enantio

187 omparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline,

188 Pregabalin prevented the N13 SEP modulation associated w

189 Pregabalin provided significantly improved treatment out

190 Compared with placebo, pregabalin (ratio of means [RoM], 0.38; 95% CI, 0.18-0.7

191 n of GluK1 proteins in HEK293 cells, whereas pregabalin reduced GluK1 proteins in cerebellar synaptos

192 The study revealed that pregabalin reduces the readily releasable pool of synapt

193 Previous studies have shown that pregabalin reduces the release of neurotransmitters in s

194 mg/kg dose could induce CPP in mice and that pregabalin-rewarding properties were mediated through gl

195 cinnarizine (RoM, 0.45; 95% CI, 0.28-0.72), pregabalin (RoM, 0.57; 95% CI, 0.33-0.96), valproate (Ro

196 flunarizine (RR, 4.00; 95% CI, 1.38-11.55), pregabalin (RR, 1.88; 95% CI, 1.13-3.14), and cinnarizin

197 Pregabalin [S-[+]-3-isobutylGABA or (S)-3-(aminomethyl)-

198 re, we investigated the role of glutamate in pregabalin-seeking behavior with ceftriaxone (CEF), a po

199 Additionally, while pregabalin significantly reduced deep dorsal horn evoked

200 Pregabalin significantly reduced mean (SD) pain scores b

201 his randomized crossover trial indicate that pregabalin significantly reduced pain and itch scores fr

202 As early as the week 1 observation, pregabalin significantly reduced the total Hamilton anxi

203 e CaV2.1 (P/Q-type) calcium channel subunit, pregabalin slowed the speed of SD propagation in vivo.

204 Notably, pregabalin (SMD -0.55, 95% CI -0.92 to -0.18) and gabape

205 iptyline supplemented with pregabalin (A-P), pregabalin supplemented with amitriptyline (P-A), and du

206 amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxeti

207 The gabapentinoids, gabapentin, and pregabalin, target the a(2)d subunits of voltage-gated c

208 by 4.5 points, among participants receiving pregabalin than among those receiving placebo (P<0.001),

209 entation rates were significantly lower with pregabalin than with 0.5 mg of pramipexole.

210 roved or much improved was also greater with pregabalin than with placebo (71.4% vs. 46.8%, P<0.001).

211 40 or 52 weeks was significantly lower with pregabalin than with pramipexole at a dose of 0.5 mg (2.

212 the development of a new synthetic route for pregabalin that proceeds with an overall yield of 74%.

213 of suicidal ideation in the group receiving pregabalin, three in the group receiving 0.25 mg of pram

214 SEP and that this modulation is prevented by pregabalin, thus suggesting that N13 SEP may reflect cha

215 Furthermore, the ability of pregabalin to alleviate mechanical hypersensitivity is l

216 FM4-64 to determine details of the action of pregabalin to reduce neurotransmitter release.

217 However, among the pregabalin-treated group, there was a marked increase in

218 week 6 between the 150 mg twice daily target pregabalin treatment and placebo.

219 tings of pain intensity, between each of the pregabalin treatment groups and the placebo group.

220 Our results indicate that pregabalin treatment, at concentrations that are therape

221 d no withdrawal syndrome was associated with pregabalin treatment.

222 ondary hot flash efficacy end points between pregabalin treatments and placebo.

223 tudy, we investigated the abuse potential of pregabalin using conditioned place preference (CPP) para

224 ulticenter, double-blind randomized trial of pregabalin versus placebo was conducted.

225 %] efficacious; and 47 of 126 [37.3%] quit), pregabalin was 0.69 (95% CrI, 0.55-0.84; 11 of 73 [15.1%

226 The effect of pregabalin was a mild but significant reduction in itch

227 ts with a history of cardiovascular disease, pregabalin was associated with an elevated HF risk compa

228 ms, being more evident with the higher dose, pregabalin was generally well tolerated by most patients

229 Pregabalin was significantly more efficacious than place

230 In a controlled trial, the novel agent pregabalin was studied for the treatment of patients wit

231 Pregabalin was well tolerated and improved global measur

232 -mg pregabalin groups, but not by the 450-mg pregabalin (week 1, P = .06; week 4, P = .32) and the al

233 f randomized clinical trials, topiramate and pregabalin were associated with reduction in headache fr

234 oembolic stroke patients, whereas gabapentin/pregabalin were favored in subarachnoid hemorrhage, intr

235 ntin, and no double-blind RCTs investigating pregabalin, were identified.

236 ocular pressure and a promising therapeutic, pregabalin, which binds to CACNA2D1 protein and lowers i

237 The interaction of gabapentin and pregabalin with conventional antiepileptic and analgesic

238 sumption among all dosages of gabapentin and pregabalin, with a mean difference of -22.07% (95% CI, -